On Wednesday February 28, 2024, Lyell Immunopharma Reported Q4 Adjusted. EPS $(0.17) Beats $(0.23) Estimate, Sales $13.00K Down From $48.39M YoY
On Wednesday February 28, 2024, Lyell Immunopharma Reported Q4 Adjusted. EPS $(0.17) Beats $(0.23) Estimate, Sales $13.00K Down From $48.39M YoY
2024年2月28日星期三，Lyell Immunopharma公佈了經調整後的第四季度業績。每股收益（0.17）超過預期（0.23）美元，銷售額低於同比4,839萬美元
Lyell Immunopharma (NASDAQ:LYEL) reported quarterly losses of $(0.17) per share which beat the analyst consensus estimate of $(0.23) by 26.09 percent. The company reported $13.00 thousand in sales this quarter. This is a 99.97 percent decrease over sales of $48.39 million the same period last year.
萊爾免疫製藥（納斯達克股票代碼：LYEL）公佈的季度虧損爲每股0.17美元（0.17美元），比分析師共識估計的美元（0.23美元）高出26.09％。該公司報告本季度銷售額爲13,000美元。這比去年同期的4,839萬美元銷售額下降了99.97％。